指南与共识特殊人群用药治疗药物监测与药物基因组学

借鉴HIV经验优化妊娠及哺乳期妇女的药理学研究:共识声明

Optimizing Pharmacology Studies in Pregnant and Lactating Women Using Lessons From HIV: A Consensus Statement.
指南 / 共识 · Clin Pharmacol Ther · 2020-10-15

该共识声明由IMPAACT网络与WHO儿科抗逆转录病毒工作组于2019年6月联合召开研讨会,旨在为妊娠及哺乳期妇女抗逆转录病毒药物的药理学研究制定关键标准。会议讨论了伦理与监管原则、妊娠期PK/PD研究的系统方法、哺乳期研究设计及采样方法,并强烈建议在III期试验前完成临床前生殖毒理学研究,最终提出了结果设计与解释的算法。

要点

  • 妊娠期生理变化常导致抗逆转录病毒药物暴露降低,可能影响病毒学疗效。
  • 建议在III期试验前完成临床前生殖毒理学研究,以便孕妇入组或继续试验。
  • 哺乳期研究需明确乳汁类型、母亲依从性确认及暴露评估的最佳PK方法。

核心结论

  • 妊娠及哺乳期妇女入组临床试验至关重要,应基于共识标准生成药理学数据。

研究设计与样本

  • IMPAACT网络与WHO儿科抗逆转录病毒工作组于2019年6月联合召开利益相关方研讨会。

主要发现

  • 妊娠期生理变化常导致抗逆转录病毒药物暴露降低,部分情况下存在病毒学疗效降低风险。

关键数值与推荐

  • 强烈建议在III期试验前完成临床前生殖毒理学研究,以使研究方案纳入孕妇或允许入组后怀孕妇女继续试验。
  • 研讨会讨论了伦理与监管原则、妊娠期PK/PD研究的系统方法、对照组、最佳采样时间及主要终点PK参数。
  • 哺乳期研究讨论了乳汁类型、母亲依从性确认及估计暴露的最佳PK方法。
  • 会议最终制定了结果设计与解释的算法。

临床怎么用

  • 临床应关注妊娠期抗逆转录病毒药物暴露降低的风险,并参考共识算法设计及解释PK/PD研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Information on the extent of drug exposure to mothers and infants during pregnancy and lactation normally becomes available years after regulatory approval of a drug. Clinicians face knowledge gaps on drug selection and dosing in pregnancy and infant exposure during breastfeeding. Physiological changes during pregnancy often result in lower drug exposures of antiretrovirals, and in some cases a risk of reduced virologic efficacy. The International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) network and the World Health Organization (WHO)-convened Pediatric Antiretrovirals Working Group collaboratively organized a workshop of key stakeholders in June 2019 to define key standards to generate pharmacology data for antiretrovirals to be used among pregnant and lactating women; review the antiretroviral product pipeline; describe key gaps for use in low-income and middle-income countries; and identify opportunities to undertake optimal studies allowing for rapid implementation in the clinical field. We discussed ethical and regulatory principles, systemic approaches to obtaining data for pregnancy pharmacokinetic/pharmacodynamic (PK/PD) studies, control groups, optimal sampling times during pregnancy, and pharmacokinetic parameters to be considered as primary end points in pregnancy PK/PD studies. For lactation studies, the type of milk to collect, ascertainment of maternal adherence, and optimal PK methods to estimate exposure were discussed. Participants strongly recommended completion of preclinical reproductive toxicology studies prior to phase III, to allow study protocols to include pregnant women or to allow women who become pregnant after enrolment to continue in the trial. The meeting concluded by developing an algorithm for design and interpretation of results and noted that recruitment of pregnant and lactating women into clinical trials is critical.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Eke AC, Olagunju A, Momper J, et al. Optimizing Pharmacology Studies in Pregnant and Lactating Women Using Lessons From HIV: A Consensus Statement. Clin Pharmacol Ther. 2020. PMID: 32930408. doi:10.1002/cpt.2048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。